Cowen analyst Yaron Werber assumed coverage on Bluebird Bio with an Outperform. The analyst believes that investors should have a strong interest in the stock, as bluebird has a deep pipeline, and is launching three drugs in 2019-2020, with "a slew of data" coming in 2019.
Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Krispy... To see the rest of the story go to thefly.com. See Story Here